Boston Scientific Launches Resolution 360™ Clip

Montag, 17.10.2016 14:35 von

PR Newswire

MARLBOROUGH, Mass., Oct. 17, 2016 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the launch of the Resolution 360™ Clip, a novel technology designed to improve hemostatic clipping by providing physicians controlled rotation designed for more accurate clip placement. Boston Scientific will introduce the clip at the annual United European Gastroenterology Week (UEGW) in Vienna, Austria, and at the American College of Gastroenterology annual meeting in Las Vegas, Nevada.

Hemostatic clipping is used in a number of endoscopy procedures of the upper and lower gastrointestinal (GI) tract to stop and help prevent bleeding associated with conditions including peptic ulcers, polyps removed during a colonoscopy and diverticulosis of the colon.  There are more than 240,000 incidences of GI bleeding in the U.S. each year1 and worldwide a 10 percent mortality rate is associated with upper and lower GI bleeds.2 A retrospective study demonstrated that prophylactic clipping can reduce the risk of bleeding from a 9.8 percent to 1.7 percent leading to a reduction in adverse events associated with GI bleeding.3

"The Resolution 360 Clip gives me the unique advantage of controlling the movement and placement of the clip while also maneuvering the scope during the clipping procedure," said David L. Carr-Locke, MD, FRCP, FASGE, chief, Division of Digestive Diseases, Mount Sinai Beth Israel Medical Center, New York, NY. "The ability to have complete control can help improve the accuracy of clip placement and the speed of the procedure particularly in complex cases."

The device is constructed using a multi-wire braided catheter that is designed to enable the healthcare professional to rotate the device in small, controlled movements in both clockwise and counterclockwise directions, enabling the clip to be maneuvered to the target area and more accurately placed at the site of a GI bleed or a potential GI bleed. Physicians at the two conferences will have the opportunity to use the Resolution 360 Clip in a simulator to experience the device first-hand.

"We are always striving to improve our technology so that physicians have the tools they need to diagnose and treat gastrointestinal disease more easily and effectively," said Art Butcher, senior vice president and president, endoscopy. "Building on the legacy Resolution Clip and its clinically proven technology, the expanded portfolio now offers physicians more hemostatic clipping options to consider in different clinical situations and patient anatomies."

About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our product launches and product performance and impact. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; the closing and integration of acquisitions; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACTS  
Media:
Catherine Brady                              
508-683-4797
Media Relations                         
Boston Scientific Corporation          
Catherine.Brady@bsci.com   

Rosie Ireland
+44 (0)7585 403359
Media Relations – Europe
Boston Scientific Corporation
Rosie.Ireland@bsci.com

Investors:
Susie Lisa, CFA
508-683-5565 (office)
Investor Relations
Boston Scientific Corporation
investor_relations@bsci.com

References

  1. AU Loperfido S, Baldo V,Piovesana E, Bellina L, Rossi K, Gropps M, Caroli A, Dal BóN, Monica F, Fabris L,Salvat HH, Bassi N, Okolicsanyi L SO, Changing trends in accute upper-GI bleeding: a population-based study. Gastrointest Endosc. 2009;70(2):212.
  2. Sebastian Straube; Martin R Tramer;R. Andres Moore; Sheena Derry; Henry J. McQuay Mortality with Upper Gastrointestinal Bleeding and Perforation: Effects of Time and NSAID USE. BMC Gastroenterology, 2008.
  3. Liaquat H, Rohn E, Rex DK. "Prophylactic Clip Closure Reduced the Risk of Delayed Postpolypectomy Hemorrhage: Experience in 277 Clipped Large Sessile or Flat Colorectal Lesions and 247 Control Lesions." Gastrointest Endosc. 2013 Mar;77(3):401-7. doi: 10.1016/j.gie.2012.10.024. Epub 2013 Jan 11. N.p., n.d. Web. < http://www.ncbi.nlm.nih.gov/pubmed/23317580 >.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/boston-scientific-launches-resolution-360-clip-300345283.html

SOURCE Boston Scientific Corporation